@ JaredSykes - g'day!! Welcome to the CDX boards, and...

@ JaredSykes - g'day!!

Welcome to the CDX boards, and congratulations on your MYQ success - I am still holding around 40k MYQ, and it will be interesting to see if they can actually get users to regularly pay for their solutions.

The next 6 months should clearly answer that remaining query, and the company will do extremely well if users do actually regularly use their services.

On CDX, I think you will find that shareholder expectations are very high - as it has:

Unique tech that is already FDA approved.
It is "playing" in huge markets (massive TAM).
It has partnerships with massive companies already in place (MOBVOI - googles partner in China, ANDON etc).
Very strong & switched on management (despite what one certain poster keep crapping on about).
A number of new products to be launched this year.
The new products should bring large product $ sales - and importantly it should also bring large amount of recurring monitoring revenues.
One of the recent announcements quoted Craig Copper (from memory) talking about a single sales order of 10,000 units for one of the new products.
And CDX already has revenues of over $4.2m per year (and the latest update suggested revenue increases on around 30%) - and is not too far from being cash flow break even (even without the new products).

I am seriously overweight already in this stock, but as you can probably tell, I find it very hard to believe CDX only has a market cap of around $70m?

If you can, have a read of the MST Access Report from 2 October 2020. Whilst the report was commissioned by CDX, it does provide a very good summary.

By 30 June 2023 (just under 2.5 years time), the MST projections for CDX were:

Revenue: $13.6m
EBIT: $ 2.69m
NPAT: $ 2.18m
EPS: 3.21 cents

Now those numbers (if achieved) would make the current 7.5 cents share price look pretty cheap

Have a great weekend everyone.